PUVA-induced Bullous Pemphigoid in Psoriasis by Nina Caca Biljanovska et al.
ACTA DERMATOVENEROLOGICA CROATICA214
PUVA-induced Bullous Pemphigoid in Psoriasis
Nina Caca-Biljanovska, Irina Arsovska-Bezhoska, Marija V’lckova-
Laskoska










Received: December 29, 2015
Accepted: July 15, 2016
Acta Dermatovenerol Croat                                 2016;24(3):214-217                                      CASE REPORT
ABSTRACT The association between psoriasis vulgaris and bullous pemphi-
goid is due to the still unclear autoimmune process. The common disease site 
is the dermo-epidermal junction or basal membrane zone (BMZ), with specific 
alterations for both diseases. Photochemotherapy (PUVA) is one of the thera-
peutic modalities for psoriasis and can trigger production of autoantibodies 
against antigens in the BMZ in patients with subclinical bullous pemphigoid. 
Furthermore, PUVA therapy can alter the immunological milieu and hence can 
contribute to the expression of bullous pemphigoid in patients with psoria-
sis. We observed a bullous eruption compatible with bullous pemphigoid in a 
psoriatic patient treated with PUVA. We speculate that the cumulative dose of 
PUVA sufficient for triggering blister formation is individually determined. 
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INTRODUCTION
There are reports in the literature concerning the 
association between psoriasis vulgaris and autoim-
mune bullous diseases such as pemphigus vulgaris 
(1), pemphigus herpetiformis (2) pemphigus foliaceus 
(3), bullous pemphigoid (4), linear immunoglobulin A 
(IgA) bullous diseases (5), and epidermolysis bullosa 
acquisita (6). Another bullous disease that targets the 
200k Da molecule (anti-laminin γ1 pemphigoid) (7,8) 
as well as the so-called psoriasis bullosa acquisita 
were recently added to that list (9).The autoimmune 
process is common for all these diseases. It not only 
provokes blister lesions on psoriatic skin but also af-
fects normal-appearing skin. Sometimes the trigger 
for these associations are therapeutic modalities for 
psoriasis itself. The exact pathogenic mechanism for 
the expression of a combination of psoriasis vulgaris 
with another autoimmune bullous disease is not well 
understood. We report a case of a man with long-
standing plaque psoriasis who developed bullous 
pemphigoid in the early course of PUVA therapy. This 
case is an example of the appearance of bullous pem-
phigoid in a patient who already suffers from psoria-
sis vulgaris, as well as the individual effect of the cu-
mulative dose of UVA as a potential trigger.
CASE REPORT
We present a case of 58-year-old male with a 
history of chronic plaque psoriasis of more than 20 
years. Four years ago he was briefly treated with 
methotrexate (MTX) 15 mg/weekly for a generalized 
episode of psoriasis, but the therapy was discontin-
ued because of lack of compliance by the patient. He 
applied therapy for psoriasis irregularly, not includ-
ing UVB and PUVA therapy. He was admitted to our 
Department with worsening psoriatic lesions, and 
PUVA therapy was an indication. Prior to PUVA ini-
tiation, we obtained laboratory analyses (including 
a complete blood count and basic metabolic panel) 
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and performed ophthalmological examination of the 
patient, echosonography of the abdomen for possi-
ble hepatic lesions, chest radiography, and testing for 
AFP and CEA tumor markers. All findings were unre-
markable. Indirect immunofluorescence (IIF) test was 
not performed. After a cumulative PUVA dose of 33.6 
J/cm2 he developed a solitary bullous lesion on his 
left arm restricted to the psoriatic plaque in regres-
sion (Figure 1). The Nikolsky sign was negative. Two 
days later there were multiple large tense blisters on 
his trunk and extremities that were not limited only 
to the psoriatic plaques but were also distributed 
over the normal-appearing skin. There was no muco-
sal or ocular involvement. The patient had not taken 
other medications. A biopsy specimen obtained from 
the border of a bulla that had arisen on psoriatic skin 
showed changes consistent with psoriasis vulgaris 
and subepidermal bulla formation that contained eo-
sinophils. There was an inflammatory infiltrate with 
lymphocytes and eosinophils in the superficial der-
mis (Figure 2). Direct immunoflorescence testing from 
perilesional, healthy (non-psoriatic) skin revealed lin-
ear, homogeneous immunoglobulin G (IgG) and C3 
deposits along the epidermal basement membrane 
zone (Figure 3). 
Considering all these findings, the primary diag-
nosis (psoriasis) was changed to PUVA-induced bul-
lous pemphigoid in psoriasis. PUVA therapy was with-
drawn. After a test dose of 2.5 to 5.0 mg MTX followed 
by a blood count 5 days later, the therapy with MTX 
at a dose of 10 mg/week was started with folic acid 
supplementation, along with topical steroids. There 
were no new blisters after two weeks of therapy, and 
mild improvement of the plaque psoriatic lesions was 
noted. After 4 weeks of treatment, remission of pso-
riasis with residual hyperpigmentation was observed 
along with healing of blisters and erosions without 
scarring or milia formation. During the follow-up pe-
riod of one year with tapering of the MTX dose, no re-
lapses of both conditions, psoriatic and bullous, were 
registered.
Figure 1. A few early bullae on the anterior aspect of the 
upper arm and a large psoriatic plaque in regression on 
the lateral side of the trunk. 
Figure 2. Subepidermal blister formation containg a few 
eosinophils. Complete dermoepidermal separation and 
“naked” dermal papillae. Inflammatory infiltrate with 
lymphocytes and eosinophils in superficial dermis. 
Figure 3. Direct immunofluorescence of perilesional 
skin revealed linear-homogeneous, band-like IgG and C3 
deposits along the epidermal basement membrane zone.
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DISCUSSION
Association between psoriasis and subepidermal 
bullous diseases was reported for the first time by 
Bloom in 1929 (10). In 1985 Grattan (11) described the 
coexistence of psoriasis vulgaris and bullous pemphi-
goid without treatment. 
The main disease site in the pathogenesis of bul-
lous pemphigoid is the basement membrane zone 
(BMZ). There are changes in the BMZ that are due to 
psoriasis vulgaris itself. As was discovered by Alvin J. 
Cox (12), basal lamina in psoriasis vulgaris has shown 
reduplication and focal discontinuity. The onset of 
blisters, primarily on psoriatic plaques, was due to 
changes of the basal lamina of psoriatic lesions that 
can expose, alter, or unmask its antigens (13). Bullous 
pemphigoid lesions limited to psoriatic plaques were 
developed because antigens at these sites were un-
masked through enzymatic degradation of the BMZ 
(14). Despite that, herniation of basal keratinocytes 
in the lamina densa (14) takes place, providing easier 
access to antibodies and can thus initiate autoim-
munity (15). All these events are independent of UVA 
light and can be sufficient to provoke subepidermal 
blisters limited to psoriatic skin. These hypothetical 
steps in the pathogenesis of bullous pemphigoid in 
patients with psoriasis does not explain bullous le-
sion on clinically healthy, non-psoriatic skin. They 
can, however, explain rare reports of the occurrence 
of bullous pempigoid in psoriatic individuals without 
using anti-psoriatic systemic therapy (16,17). Among 
anti-psoriatic systemic therapeutics, photochemo 
(PUVA) is most commonly suspected of triggering 
bullous pemphigoid. It was suggested that PUVA 
may precipitate bullous pemphigoid by immunologi-
cal alteration of the epidermal antigens. The result 
is formation of complement-binding anti-BMZ anti-
bodies leading to bullous skin lesions (18). Washio et 
al. (19) suggested alteration of the BMZ antigenicity 
by UV radiation that might lead to exposing or releas-
ing altered antigens and consequently stimulation of 
autoantibody production. Danno et al. hypothesized 
that alteration of the membrane markers by PUVA 
might be due to the reaction of PUVA and membrane 
glycoproteins (20). Bullous pemphigoid antigen 
(BPAG) (230kDa BP antigen) as an intracellular plaque 
protein and BPAG2 (180kDa BP antigen) as a trans-
membrane collagenous protein take part in form-
ing hemidesmosomes. Kitajima et al. (21) noted that 
BPAG2 internalization takes part in weakening the 
hemidesmosomes. This is especially important when 
basal cells enter mitosis, because there is a process of 
reconstruction of hemidesmosomes during mitotic 
activity that would be difficult to achieve if there is a 
shortage of BPAG2 due to its internalization. On the 
other hand, the effect of PUVA-inducing interruption/
blockade of the mitotic activity in cells is well known. 
This shortage of BPAG2 and the antiproliferative ef-
fect of PUVA inevitably leads to subepidermal blister 
formation.
From the immunological point of view, bullous 
pemphigoid is regarded as a Th2-mediated disease. 
During PUVA therapy there is a switch in cytokine ex-
pression from Th1 to Th2 (22). This new immunologi-
cal milieu in patients with subclinical bullous pem-
phigoid, patients with hidden susceptibility, might 
lead to clinical expression of bullous pemphigoid. 
PUVA, UVA, and UVB have already been described as 
a possible mode of therapy that can provoke bullous 
pemphigoid formation (23-25). This was the case in 
our patient treated with PUVA therapy. Regarding the 
cumulative dose of UVA sufficient to induce bullous 
pemphigoid in psoriasis, Bernadas et al. (26) present-
ed a patient who had developed bullae after receiv-
ing a cumulative dose of UVA of 673 J/cm2 and UVB of 
2.96 J/cm2. In contrast to that case report, our patient 
developed bullous pemphigoid after the administra-
tion of a cumulative dose of UVA of only 33.6 J/cm2 
and without previous UVA or UVB phototherapy.  
CONCLUSION
We speculate that the cumulative dose of UVA 
which is sufficient to provoke blisters on psoriatic 
plaques in susceptible patients is individually deter-
mined. 
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